{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:40:06Z","timestamp":1789080006525,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019590","name":"CARB-X","doi-asserted-by":"publisher","award":["06CARB-X0948"],"award-info":[{"award-number":["06CARB-X0948"]}],"id":[{"id":"10.13039\/100019590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128694","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:02:14Z","timestamp":1779494534000},"page":"128694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Consultation report - gonococcal immunoassays and standards for vaccine development"],"prefix":"10.1016","volume":"86","author":[{"given":"C.A.","family":"MacLennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gorringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Criss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Isbrucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.W.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vipond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Delany-Moretlwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Finco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vichos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rhyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Bash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stickings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128694_bb0005","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128694_bb0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/humupd\/dmv016","article-title":"Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century","volume":"21","author":"Inhorn","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.vaccine.2026.128694_bb0015","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(97)02190-9","article-title":"Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128694_bb0020","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128694_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1248613","article-title":"Immune responses to Neisseria gonorrhoeae and implications for vaccine development","volume":"14","author":"Belcher","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0030","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf; 2016 [accessed 2 November 2022]."},{"key":"10.1016\/j.vaccine.2026.128694_bb0035","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128694_bb0040","unstructured":"World Health Organization. WHO preferred product chacacteristics for gonococcal vaccines. https:\/\/iris.who.int\/bitstream\/handle\/10665\/349342\/9789240039827-eng.pdf; 2021 [accessed 12 January 2026]."},{"key":"10.1016\/j.vaccine.2026.128694_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127180","article-title":"Cross-protection of meningococcal B vaccines against gonorrhea: a systematic review and meta-analysis","volume":"56","author":"Georgiadis","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128694_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/infdis\/jiae383","article-title":"Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis","volume":"231","author":"Abara","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0055","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128694_bb0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0065","unstructured":"UK Health Security Agency. Surveillance of targeted 4CMenB vaccination to protect individuals at higher risk of gonorrhoea. https:\/\/www.gov.uk\/government\/publications\/surveillance-of-4cmenb-vaccination-to-protect-individuals-at-higher-risk-of-gonorrhoea; 2025 [accessed February 10 2026]."},{"key":"10.1016\/j.vaccine.2026.128694_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design","volume":"24","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101433","article-title":"Outer membrane vesicle vaccines","volume":"50","author":"Micoli","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01190-1","article-title":"A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice","volume":"10","author":"Spinsanti","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128694_bb0085","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1172\/JCI112167","article-title":"Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae","volume":"76","author":"Joiner","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128694_bb0090","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.164.5.1735","article-title":"Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum","volume":"164","author":"Rice","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2026.128694_bb0095","article-title":"Antibodies with higher bactericidal activity induced by a Neisseria gonorrhoeae Rmp deletion mutant strain","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128694_bb0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/jiv024","article-title":"Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model","volume":"212","author":"Gulati","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0105","unstructured":"Fierce Biotech. GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'. https:\/\/www.fiercebiotech.com\/biotech\/gsk-axes-vaccine-21b-deal-switching-preclinical-successor-over-increased-competition; 2024 [accessed 12 January 2026]."},{"key":"10.1016\/j.vaccine.2026.128694_bb0110","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/infdis\/jit354","article-title":"Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12","volume":"208","author":"Liu","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0115","doi-asserted-by":"crossref","unstructured":"Liu Y, Hammer LA, Daamen J, Stork M, Egilmez NK, Russell MW. Microencapsulated IL-12 drives genital tract immune responses to intranasal gonococcal outer membrane vesicle vaccine and induces resistance to vaginal infection with diverse strains of Neisseria gonorrhoeae. mSphere 2023;8:e0038822. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36537786.","DOI":"10.1128\/msphere.00388-22"},{"key":"10.1016\/j.vaccine.2026.128694_bb0120","unstructured":"Freixeiro P, Lewis LA, Sanchez-Buso L, Unemo M, Gulati S, Linder A, et al. Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB. NPJ Vaccines. in press."},{"key":"10.1016\/j.vaccine.2026.128694_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012688","article-title":"Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design","volume":"20","author":"Jones","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128694_bb0130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/infdis\/jiab450","article-title":"Meningococcal detoxified outer membrane vesicle vaccines enhance gonococcal clearance in a murine infection model","volume":"225","author":"Matthias","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0135","doi-asserted-by":"crossref","unstructured":"Giuntini S, Tefera SW, Bolanos A, Ramos Rivera A, Moe GR. A combination native outer membrane vesicle (NOVM) vaccine to prevent meningococcal and gonococcal disease. Pathogens 2025;14. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/41156589.","DOI":"10.20944\/preprints202508.2055.v1"},{"key":"10.1016\/j.vaccine.2026.128694_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection","volume":"9","author":"Gulati","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128694_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02552-19","article-title":"Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine","volume":"10","author":"Gulati","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128694_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00247","article-title":"Utility of hybrid transferrin binding protein antigens for protection against pathogenic Neisseria species","volume":"10","author":"Fegan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123182","article-title":"Gonococcal microparticle vaccine in dissolving microneedles induced immunity and enhanced bacterial clearance in infected mice","volume":"642","author":"Bagwe","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2026.128694_bb0160","unstructured":"Carranza P, Lipowski G, Yates L, Serventi F, Fleurkens S, Seib KL, et al. Immunogenicity and functionality of a N. Gonorrhoeae vaccine (LTB-NG6) in animals. 24th International Pathogenic Neisseria Conference. Florence, Italy 2025."},{"key":"10.1016\/j.vaccine.2026.128694_bb0165","doi-asserted-by":"crossref","first-page":"1688536","DOI":"10.3389\/fimmu.2025.1688536","article-title":"Preclinical in vivo evaluation of a gonococcal multivalent vaccine containing antigens identified by CASS","volume":"16","author":"Roe","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/gen.45.03.15","article-title":"New mRNA vaccines target a host of viral and bacterial pathogens","volume":"45","author":"Seydel","year":"2025","journal-title":"Genetic Engineering & Biotechnology News"},{"key":"10.1016\/j.vaccine.2026.128694_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/978-1-4939-9496-0_25","article-title":"Experimental human infection with Neisseria gonorrhoeae","volume":"1997","author":"Hobbs","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0180","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1128\/IAI.67.8.3937-3946.1999","article-title":"Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections","volume":"67","author":"Hedges","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128694_bb0185","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128694_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00309-23","article-title":"Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine","volume":"91","author":"Gray","year":"2023","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128694_bb0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-0716-1900-1_19","article-title":"Assessment of serum bactericidal and opsonophagocytic activity of antibodies to gonococcal vaccine targets","volume":"2414","author":"Semchenko","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0200","unstructured":"Mestecky J, Strober W, Russell MW, Cheroutre H, Lambrecht BN, Kelsall BL. Mucosal Immunology. 4th ed. Oxford: Academic Press; 2015."},{"key":"10.1016\/j.vaccine.2026.128694_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00095-11","article-title":"Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1\/Th2 by treatment with anti-transforming growth factor \u03b2 antibody generates immunological memory and protective immunity","volume":"2","author":"Liu","year":"2011","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128694_bb0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-\u03b2-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/mi.2013.36","article-title":"Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells","volume":"7","author":"Liu","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0220","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128694_bb0225","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiv211","article-title":"The diversity of meningococcal carriage across the African Meningitis Belt and the impact of vaccination with a group A meningococcal conjugate vaccine","volume":"212","author":"MenAfriCar Consortium","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128694_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128694_bb0240","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0245","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/1873-3468.13760","article-title":"Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, and evasion mechanisms","volume":"594","author":"Lewis","year":"2020","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2026.128694_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000323","article-title":"Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody","volume":"17","author":"Gulati","year":"2019","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126508","article-title":"Development and validation of a standardized human complement serum bactericidal activity assay to measure functional antibody responses to Neisseria gonorrhoeae","volume":"43","author":"Matthias","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128694_bb0260","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2666-5247(23)00258-6","article-title":"The importance of using WHO international standards to harmonise SARS-CoV-2 serological assays","volume":"5","author":"Hempel","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128694_bb0265","unstructured":"World Health Organization. Proposed First WHO International Standard for antibodies to gonococcus (serum). In: WHO Expert Committee on Biological Standardization. Sevety-seventh report. https:\/\/www.who.int\/publications\/i\/item\/9789240078116; 2023 [accessed 28 January 2026]."},{"key":"10.1016\/j.vaccine.2026.128694_bb0270","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/infdis\/jiab462","article-title":"Critical needs in advancing Shigellavaccines for global health","volume":"225","author":"MacLennan","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0275","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro.2017.169","article-title":"Neisseria gonorrhoeae host adaptation and pathogenesis","volume":"16","author":"Quillin","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128694_bb0280","article-title":"Bacterium of one thousand and one variants: genetic diversity of Neisseria gonorrhoeae pathogenicity","volume":"9","author":"Kurzyp","year":"2023","journal-title":"Microb Genom"},{"key":"10.1016\/j.vaccine.2026.128694_bb0285","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2026.128694_bb0290","doi-asserted-by":"crossref","unstructured":"Harrison OB, Cehovin A, Skett J, Jolley KA, Massari P, Genco CA, et al. Neisseria gonorrhoeae population genomics: use of the gonococcal core genome to improve surveillance of antimicrobial resistance. J Infect Dis 2020;222:1816\u201325. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32163580.","DOI":"10.1093\/infdis\/jiaa002"},{"key":"10.1016\/j.vaccine.2026.128694_bb0295","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.107758.3","article-title":"Neisseria gonorrhoeae LIN codes provide a robust, multi-resolution lineage nomenclature","volume":"14","author":"Unitt","year":"2025","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2026.128694_bb0300","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0305","doi-asserted-by":"crossref","unstructured":"Abara WE, Bernstein KT, Lewis FMT, Schillinger JA, Feemster K, Pathela P, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis 2022;22:1021\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35427490.","DOI":"10.1016\/S1473-3099(21)00812-4"},{"key":"10.1016\/j.vaccine.2026.128694_bb0310","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0315","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1093\/cid\/ciaf372","article-title":"Long-term protection against invasive meningococcal B disease and gonococcal infection 5 years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study","volume":"81","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0320","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","article-title":"Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California","volume":"76","author":"Bruxvoort","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0325","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/OLQ.0000000000001771","article-title":"Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study","volume":"50","author":"Raccagni","year":"2023","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2026.128694_bb0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31742","article-title":"Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students","volume":"6","author":"Robison","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128694_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126312","article-title":"Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: a retrospective study","volume":"42","author":"Abara","year":"2024","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:23:29Z","timestamp":1785353009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"alternative-id":["S0264410X26005025"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128694","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consultation report - gonococcal immunoassays and standards for vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128694"}}